Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cipher Pharmaceuticals Enters U.S. Market | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cipher Pharmaceuticals Enters U.S. Market

Accelerates development of a leading North American dermatology company

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cipher Pharmaceuticals Inc. has acquired Charleston, SC-based Innocutis Holdings LLC, a privately held specialty dermatology company, for $45.5 million.

The acquisition marks Canada-based Cipher’s commercial entry to the U.S. market.

“Innocutis provides us with commercial infrastructure, revenue-generating branded prescription products, and a talented team, including a 31-person sales force that shares our customer-focused philosophy,” said Shawn O’Brien, president and chief executive officer of Cipher. “We see excellent opportunity to drive increased sales and profitability by growing their current branded prescription products, led by Sitavig, and adding new products to the portfolio, including our recently acquired Pruridexin and Dermadexin.”

“Today’s transaction marks the start of a new chapter as part of the Cipher organization, as well as the opportunity to participate in the significant upside potential of the combined company,” said Joe Pecora, president and chief executive officer of Innocutis. “We are combining with a partner that is ideally suited to realize the full potential inherent in Sitavig, a treatment breakthrough for herpes labialis. The product was recently launched in the U.S. and will be filed in Canada in 2016.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters